Don M Benson, MD, PhD

College

College of Medicine

Department/Division

Internal Medicine

Academic Title

Professor-Clinical

Research Program

Molecular Carcinogenesis and Chemoprevention

Research Interest

Multiple Myeloma ● Cancer ● Lymphoma, Non-Hodgkin ● Graft vs Host Disease ● Amyloidosis ● Leukemia, Lymphocytic, Chronic, B-Cell ● Lymphoma ● Fatigue ● Leukemia, Myeloid, Acute ● Melanoma

Don Benson Jr., MD PhD, FACP, is a member of the Molecular Carcinogenesis and Chemoprevention Program at the OSUCCC – James, where he and his multidisciplinary, subspecialized team care for patients with multiple myeloma and amyloidosis, as well as those undergoing blood and marrow stem cell transplantation.

Following his internal medicine residency at the University of Virginia, Dr. Benson came to The Ohio State University to complete his subspecialty training in clinical oncology and his postdoctoral laboratory training. He joined the faculty at Ohio State in 2006 and holds the rank of associate professor of medicine. He is ABIM board certified in medical oncology and holds a Fellowship in the American College of Physicians.

Dr. Benson also serves as the interim director of the Division of Hematology, as well as the division’s head of translational research, where he helps facilitate the connection of new laboratory discoveries to clinical trials for patients with cancer. His research interests are focused in the development of immune-based therapy for multiple myeloma and other cancers.

Dr. Benson also serves as the division’s head of translational research, where he helps facilitate the connection of new laboratory discoveries to clinical trials for patients with cancer. His research interests are focused in the development of immune-based therapy for multiple myeloma and other cancers.

Work by his laboratory team has helped bring new immune-based and targeted therapies to clinical use. In addition to laboratory-based research, Dr. Benson has led over 100 therapeutic clinical trials as principal or co-principal investigator in which he has tested promising novel treatments for cancer. His team has published over 90 peer-reviewed research manuscripts in the most eminent journals of the field, and they have presented their research findings in over 100 abstracts and presentations at scientific meetings around the world.

Dr. Benson is also involved in Ohio State’s medical education mission and has received both the Professor of the Year Award (2012) and the Distinguished Educator Award (2016) from The Ohio State University College of Medicine.

Education

BA, Wheeling Jesuit College

Wheeling, WV (USA)
Fellowship, The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Columbus, OH (USA)
Fellowship, The Ohio State University College of Medicine

Columbus, OH (USA)
Fellowship, The Ohio State University College of Medicine

Columbus, OH (USA)

Residencies

Chief Medical Resident & Instructor of Clinical Internal Medicine

University of Virginia School of Medicine

Charlottesville, VA (USA)
Intern and Resident, Internal Medicine

University of Virginia Health Sciences Center

Charlottesville, VA (USA)

Fellowship

Assistant Professor of Medicine and Coordinator of Education Division of Hematology, Department of Internal Medicine

The Ohio State University College of Medicine

Columbus, OH (USA)
Associate Professor of Medicine and Coordinator of Education, Division of Hematology, Department of Internal Medicine

The Ohio State University College of Medicine

Columbus, OH (USA)
Clinical Instructor – Housestaff, Division of Hematology/Oncology Department of Medicine, and Postdoctoral Fellow

The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Columbus, OH (USA)

Office Location

A445 Starling Loving Hall

320 W 10th Ave, Columbus, OH 43210

614-366-3802

614-293-7526

benson.236@osu.edu;DON.BENSON@OSUMC.EDU

Publications

Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience.

Yucebay F, Matthews C, Puto M, Li J, William B, Jaglowski SM, Penza SL, Vasu S, Benson DM, Andritsos LA, Devine SM, Efebera YA, Roddy JVF

Leuk Lymphoma in press 1-7 02/15/2019
BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas.

Singer S, Sharma N, Dean R, Zhao Q, Abounader D, Elder P, Hofmeister CC, Benson DM, Rosko A, Penza S, Andritsos L, Vasu S, Jaglowski S, William BM, Bolwell B, Pohlman B, Kalaycio M, Jagadeesh D, Hill B, Sobecks R, Devine SM, Majhail NS, Efebera YA

Bone Marrow Transplant in press 02/04/2019
Design, synthesis and evaluation of anti-CD38 antibody drug conjugate based on Daratumumab and maytansinoid.

Zhang X, Zhang C, Yang X, Hou X, Zhao W, Benson D, Yu J, Dong Y

Bioorg Med Chem 27 479-482 02/01/2019
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma.

Singer S, Dean R, Zhao Q, Sharma N, Abounader D, Elder P, Hofmeister CC, Benson DM, Rosko A, Penza S, Andritsos L, Vasu S, Jaglowski S, William BM, Bolwell B, Pohlman B, Kalaycio M, Jagadeesh D, Hill B, Sobecks R, Devine SM, Majhail NS, Efebera YA

Biol Blood Marrow Transplant in press 02/01/2019
Pilot randomized controlled trial of a symptom cluster intervention in advanced cancer.

Wells-Di Gregorio SM, Marks DR, DeCola J, Peng J, Probst D, Zaleta A, Benson D, Cohn DE, Lustberg M, Carson WE, Magalang U

Psychooncology 28 76-84 01/01/2019
The IL-15-AKT-XBP1s signaling pathway contributes to effector functions and survival in human NK cells.

Wang Y, Zhang Y, Yi P, Dong W, Nalin AP, Zhang J, Zhu Z, Chen L, Benson DM, Mundy-Bosse BL, Freud AG, Caligiuri MA, Yu J

Nat Immunol 20 10-17 01/01/2019
Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?

Vaughn JL, Zhao Q, Epperla N, Puto M, Roddy J, Elder P, Blum W, Klisovic R, Jaglowski S, Penza S, William B, Andritsos L, Brammer JE, Hofmeister C, Efebera Y, Benson D, Devine S, Cataland S, Vasu S

Bone Marrow Transplant in press 11/09/2018
Psychosocial risk predicts high readmission rates for hematopoietic cell transplant recipients.

Richardson DR, Huang Y, McGinty HL, Elder P, Newlin J, Kirkendall C, Andritsos L, Benson D, Blum W, Efebera Y, Penza S, Hofmeister C, Jaglowski S, Klisovic R, Vasu S, William B, Devine S, Rosko AE

Bone Marrow Transplant 53 1418-1427 11/01/2018
Ninety-minute daratumumab infusion is safe in multiple myeloma.

Barr H, Dempsey J, Waller A, Huang Y, Williams N, Sharma N, Benson DM, Rosko AE, Efebera YA, Hofmeister CC

Leukemia 32 2495-2518 11/01/2018
Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function.

Scoville SD, Nalin AP, Chen L, Chen L, Zhang MH, McConnell K, Beceiro Casas S, Ernst G, Traboulsi AA, Hashi N, Williams M, Zhang X, Hughes T, Mishra A, Benson DM, Saultz JN, Yu J, Freud AG, Caligiuri MA, Mundy-Bosse BL

Blood 132 1792-1804 10/25/2018
Most multiple myeloma patients have low testosterone.

John S, Sharma N, Sborov DW, Williams N, Jones D, Benson DM, Efebera YA, Rosko AE, Vincent J, Hofmeister CC

Leuk Lymphoma in press 1-3 10/02/2018
Fratricide of NK Cells in Daratumumab Therapy for Multiple Myeloma Overcome by Ex Vivo-Expanded Autologous NK Cells.

Wang Y, Zhang Y, Hughes T, Zhang J, Caligiuri MA, Benson DM, Yu J

Clin Cancer Res 24 4006-4017 08/15/2018
Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia.

Buteyn NJ, Fatehchand K, Santhanam R, Fang H, Dettorre GM, Gautam S, Harrington BK, Henderson SE, Merchand-Reyes G, Mo X, Benson DM, Carson WE 3rd, Vasu S, Byrd JC, Butchar JP, Tridandapani S

Int Immunol 30 375-383 07/24/2018
Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant.

Rosko AE, Huang Y, Benson DM, Efebera YA, Hofmeister C, Jaglowski S, Devine S, Bhatt G, Wildes TM, Dyko A, Jones D, Naughton MJ, Byrd JC, Burd CE

J Geriatr Oncol in press 07/05/2018
A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma.

Chan WK, Kang S, Youssef Y, Glankler EN, Barrett ER, Carter AM, Ahmed EH, Prasad A, Chen L, Zhang J, Benson DM Jr, Caligiuri MA, Yu J

Cancer Immunol Res 6 776-787 01/01/2018
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.

Sborov DW, Canella A, Hade EM, Mo X, Khountham S, Wang J, Ni W, Poi M, Coss C, Liu Z, Phelps MA, Mortazavi A, Andritsos L, Baiocchi RA, Christian BA, Benson DM, Flynn J, Porcu P, Byrd JC, Pichiorri F, Hofmeister CC

Leuk Lymphoma 58 2310-2318 10/01/2017
Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial.

Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Tackett K, Williams N, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Hofmeister CC, Phelps MA

Clin Pharmacol Ther 102 511-519 09/01/2017
Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial.

Cho YK, Sborov DW, Lamprecht M, Li J, Wang J, Hade EM, Gao Y, Tackett K, Williams N, Benson DM, Efebera YA, Rosko AE, Devine SM, Poi M, Hofmeister CC, Phelps MA

Clin Pharmacol Ther 102 511-519 09/01/2017
A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.

Martin T, Baz R, Benson DM, Lendvai N, Wolf J, Munster P, Lesokhin AM, Wack C, Charpentier E, Campana F, Vij R

Blood 129 3294-3303 01/22/2017
Checkpoint inhibition in myeloma.

Benson DM Jr

Hematology Am Soc Hematol Educ Program 2016 528-533 12/02/2016
Checkpoint inhibition in myeloma.

Benson DM Jr

Hematology Am Soc Hematol Educ Program 2016 528-533 12/02/2016
Interferon-γ Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells.

Fatehchand K, McMichael EL, Reader BF, Fang H, Santhanam R, Gautam S, Elavazhagan S, Mehta P, Buteyn NJ, Merchand-Reyes G, Vasu S, Mo X, Benson DM Jr, Blachly JS, Carson WE 3rd, Byrd JC, Butchar JP, Tridandapani S

J Biol Chem 291 25656-25666 12/02/2016
Interferon-γ Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells.

Fatehchand K, McMichael EL, Reader BF, Fang H, Santhanam R, Gautam S, Elavazhagan S, Mehta P, Buteyn NJ, Merchand-Reyes G, Vasu S, Mo X, Benson DM Jr, Blachly JS, Carson WE 3rd, Byrd JC, Butchar JP, Tridandapani S

J Biol Chem 291 25656-25666 12/02/2016
Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.

Harshman SW, Canella A, Ciarlariello PD, Agarwal K, Branson OE, Rocci A, Cordero H, Phelps MA, Hade EM, Dubovsky JA, Palumbo A, Rosko A, Byrd JC, Hofmeister CC, Benson DM Jr, Paulaitis ME, Freitas MA, Pichiorri F

J Proteomics 136 89-98 03/16/2016
Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.

Harshman SW, Canella A, Ciarlariello PD, Agarwal K, Branson OE, Rocci A, Cordero H, Phelps MA, Hade EM, Dubovsky JA, Palumbo A, Rosko A, Byrd JC, Hofmeister CC, Benson DM Jr, Paulaitis ME, Freitas MA, Pichiorri F

J Proteomics 136 89-98 03/16/2016
Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development.

Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM Jr, Hofmainster C, Alder H, Garofalo M, Di Leva G, Volinia S, Lin HJ, Perrotti D, Kuehl M, Aqeilan RI, Palumbo A, Croce CM

Cancer Cell 30 349-351 01/08/2016
Downregulation of p53-inducible microRNAs 192, 194, and 215 Impairs the p53/MDM2 Autoregulatory Loop in Multiple Myeloma Development.

Pichiorri F, Suh SS, Rocci A, De Luca L, Taccioli C, Santhanam R, Zhou W, Benson DM Jr, Hofmainster C, Alder H, Garofalo M, Di Leva G, Volinia S, Lin HJ, Perrotti D, Kuehl M, Aqeilan RI, Palumbo A, Croce CM

Cancer Cell 30 349-351 01/08/2016
Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT).

Efebera YA, Geyer S, Andritsos L, Vasu S, Jaglowski S, Bingman A, Blum W, Klisovic R, Hofmeister CC, Benson DM, Penza S, Elder P, Cortright K, Kitzler R, Coombes K, O'Donnell L, Daneault B, Bradbury H, Zhang J, Chen X, Garman S, Ranganathan P, Yu X, Hofstetter J, Yu J, Garzon R, Scrape SR, Lozanski G, Devine SM

Biol Blood Marrow Transplant 22 71-9 01/01/2016
Tocilizumab for steroid refractory acute graft-versus-host disease.

Roddy JV, Haverkos BM, McBride A, Leininger KM, Jaglowski S, Penza S, Klisovic R, Blum W, Vasu S, Hofmeister CC, Benson DM, Andritsos LA, Devine SM, Efebera YA

Leuk Lymphoma 57 81-5 01/01/2016
Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma.

Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter SY, Canella A, Smith E, Badway J, Old M, Jaime-Ramirez AC, Yan P, Benson DM, Byrd JC, Baiocchi R, Kaur B, Hofmeister CC, Pichiorri F

Mol Cancer Ther 15 830-41 01/01/2016
Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma.

Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter SY, Canella A, Smith E, Badway J, Old M, Jaime-Ramirez AC, Yan P, Benson DM, Byrd JC, Baiocchi R, Kaur B, Hofmeister CC, Pichiorri F

Mol Cancer Ther 15 830-41 01/01/2016
Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma.

Stiff A, Caserta E, Sborov DW, Nuovo GJ, Mo X, Schlotter SY, Canella A, Smith E, Badway J, Old M, Jaime-Ramirez AC, Yan P, Benson DM, Byrd JC, Baiocchi R, Kaur B, Hofmeister CC, Pichiorri F

Mol Cancer Ther 15 830-41 01/01/2016
Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.

Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, O'Donnell LC, Bradbury H, Kitzler R, Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson DM, Muthusamy N, Lozanski G, Devine SM

Biol Blood Marrow Transplant 22 658-668 01/01/2016
Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.

Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, O'Donnell LC, Bradbury H, Kitzler R, Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson DM, Muthusamy N, Lozanski G, Devine SM

Biol Blood Marrow Transplant 22 658-668 01/01/2016
Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.

Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, O'Donnell LC, Bradbury H, Kitzler R, Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson DM, Muthusamy N, Lozanski G, Devine SM

Biol Blood Marrow Transplant 22 658-668 01/01/2016
Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy.

Vasu S, Wu H, Satoskar A, Puto M, Roddy J, Blum W, Klisovic R, Andritsos L, Hofmeister C, Benson DM, Efebera Y, Jaglowski S, Penza S, Cohen D, Devine S, Cataland S

Bone Marrow Transplant 51 1241-4 01/01/2016
Erratum to "Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease" [Biol Blood Marrow Transplant 22(2016):658-668].

Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, O'Donnell LC, Bradbury H, Kitzler R, Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson DM, Muthusamy N, Lozanski G, Devine SM

Biol Blood Marrow Transplant 22 1341 01/01/2016
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials.

Kohrt HE, Tumeh PC, Benson D, Bhardwaj N, Brody J, Formenti S, Fox BA, Galon J, June CH, Kalos M, Kirsch I, Kleen T, Kroemer G, Lanier L, Levy R, Lyerly HK, Maecker H, Marabelle A, Melenhorst J, Miller J, Melero I, Odunsi K, Palucka K, Peoples G, Ribas A, Robins H, Robinson W, Serafini T, Sondel P, Vivier E, Weber J, Wolchok J, Zitvogel L, Disis ML, Cheever MA, Cancer Immunotherapy Trials Network (CITN)

J Immunother Cancer 4 15 01/01/2016
Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma.

Sborov DW, Benson DM, Williams N, Huang Y, Bowers MA, Humphries K, Efebera Y, Devine S, Hofmeister CC

Br J Haematol 171 74-83 10/01/2015
Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma.

Rosko A, Hofmeister C, Benson D, Efebera Y, Huang Y, Gillahan J, Byrd JC, Burd CE

Bone Marrow Transplant 50 1379-81 10/01/2015
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.

Benson DM Jr, Cohen AD, Jagannath S, Munshi NC, Spitzer G, Hofmeister CC, Efebera YA, Andre P, Zerbib R, Caligiuri MA

Clin Cancer Res 21 4055-61 09/15/2015
A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma.

Benson DM Jr, Cohen AD, Jagannath S, Munshi NC, Spitzer G, Hofmeister CC, Efebera YA, Andre P, Zerbib R, Caligiuri MA

Clin Cancer Res 21 4055-61 09/15/2015
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.

Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA

Br J Haematol 169 701-10 06/01/2015
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.

Christian BA, Poi M, Jones JA, Porcu P, Maddocks K, Flynn JM, Benson DM Jr, Phelps MA, Wei L, Byrd JC, Wegener WA, Goldenberg DM, Baiocchi RA, Blum KA

Br J Haematol 169 701-10 06/01/2015
A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma.

Hofmeister CC, Williams N, Geyer S, Hade EM, Bowers MA, Earl CT, Vaughn J, Bingman A, Humphries K, Lozanski G, Baiocchi RA, Jaglowski SM, Blum K, Porcu P, Flynn J, Penza S, Benson DM, Andritsos LA, Devine SM

Leuk Lymphoma 56 1043-9 04/01/2015
Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant.

Salem G, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos L, Klisovic R, Vasu S, Blum W, Devine SM, Jaglowski S, Efebera YA

Leuk Lymphoma 56 1058-65 04/01/2015
A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma.

Sborov DW, Nuovo GJ, Stiff A, Mace T, Lesinski GB, Benson DM Jr, Efebera YA, Rosko AE, Pichiorri F, Grever MR, Hofmeister CC

Clin Cancer Res 20 5946-55 12/01/2014
A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma.

Sborov DW, Nuovo GJ, Stiff A, Mace T, Lesinski GB, Benson DM Jr, Efebera YA, Rosko AE, Pichiorri F, Grever MR, Hofmeister CC

Clin Cancer Res 20 5946-55 12/01/2014
Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study.

Bechtel T, McBride A, Crawford B, Bullington S, Hofmeister CC, Benson DM Jr, Jaglowski S, Penza S, Andritsos LA, Devine SM

Support Care Cancer 22 2911-6 11/01/2014
The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma.

Jaglowski SM, Ruppert AS, Hofmeister CC, Elder P, Blum W, Klisovic R, Vasu S, Penza S, Efebera YA, Benson DM Jr, Devine SM, Andritsos LA

Bone Marrow Transplant 49 1323-9 10/01/2014
Circulating miRNA markers show promise as new prognosticators for multiple myeloma.

Rocci A, Hofmeister CC, Geyer S, Stiff A, Gambella M, Cascione L, Guan J, Benson DM, Efebera YA, Talabere T, Dirisala V, Smith EM, Omedè P, Isaia G, De Luca L, Rossi D, Gentili S, Uccello G, Consiglio J, Ria R, Benevolo G, Bringhen S, Callea V, Weiss B, Ferro A, Magarotto V, Alder H, Byrd JC, Boccadoro M, Marcucci G, Palumbo A, Pichiorri F

Leukemia 28 1922-6 09/01/2014
The transcription Factor AHR prevents the differentiation of a stage 3 innate lymphoid cell subset to natural killer cells.

Hughes T, Briercheck EL, Freud AG, Trotta R, McClory S, Scoville SD, Keller K, Deng Y, Cole J, Harrison N, Mao C, Zhang J, Benson DM, Yu J, Caligiuri MA

Cell Rep 8 150-62 07/10/2014
Novel gelsolin variant as the cause of nephrotic syndrome and renal amyloidosis in a large kindred.

Efebera YA, Sturm A, Baack EC, Hofmeister CC, Satoskar A, Nadasdy T, Nadasdy G, Benson DM, Gillmore JD, Hawkins PN, Rowczenio D

Amyloid 21 110-2 06/01/2014
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, Spurgeon SE, Kahl BS, Bello C, Webb HK, Johnson DM, Peterman S, Li D, Jahn TM, Lannutti BJ, Ulrich RG, Yu AS, Miller LL, Furman RR

Blood 123 3390-7 05/29/2014
A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).

Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, Benson DM, Byrd JC, Peterman S, Cho Y, Yu A, Godfrey WR, Wagner-Johnston ND

Blood 123 3398-405 05/29/2014
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, Cho Y, Webb HK, Johnson DM, Yu AS, Ulrich RG, Godfrey WR, Miller LL, Spurgeon SE

Blood 123 3406-13 05/29/2014